

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☐	☒ A description of all covariates tested
☒	☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☒	☐ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
☒	☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	No data was collected and, therefore, no software was used.
Data analysis	The STATA MP/17 statistical package for windows was used to conduct all data analyses.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The data that support the findings of this study – Blueteq, National Immunisation (NIMS) Database of COVID-19, mortality (ONS), hospital admissions (HES) and SARS-CoV-2 infection data (PHE) - are not publicly available because they are based on de-identified national clinical records. Due to national and organisational data privacy regulations, individual-level data such as those used for this study cannot be shared openly.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	Sex (phenotypical) was used as a covariate in the descriptive, multi-variable, and case-series analyses for the eligible population (n=1,251,852). Sex was an assigned category and gender was not used. The data were provided by NHS Digital. Sex was included as a covariate and exposure in the case-series and uptake analyses, respectively. Gender (self-assigned) was not used in this study.
Population characteristics	All patients recorded in the extremely clinically vulnerable patients eligible for COVID-19 treatments cohort and any other patients treated with Sotrovimab in the community in England during the study period (n=1,251,852). There were 685,635 patients classified as Female and 555,369 classified as Male. 10,848 had no recorded sex.
Recruitment	No participants were recruited for this study.
Ethics oversight	National Health Service Research Ethics Committee (NHS REC) approval for use of the data in the QResearch Trusted Research Environment was obtained from East Midlands-Derby Research Ethics Committee [reference 04/03/2021]. This study was reviewed and approved by the QResearch Scientific Committee, which constitutes Research Ethics Approval under REC 23/EM/0166.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	All patients in England who fell into the following three categories were included in the initial sample (n=10,185,073). These were: all patients listed as clinically vulnerable by the NHS (n=1,265,047), patients with a positive SARS-CoV-2 test recorded during study period (n=9,087,649), and all patients recorded in the BLUTEQ database as having been treated with Sotrovimab (n=62,583).
Data exclusions	Data from patients were excluded (n=8,933,221) from the analyses if they were less than 12 years of age; had a missing NHS number; were treated with antivirals; received treatment which was unapproved or not completed by the commissioning team; were not on the eligible list; received a nMAB treatment other than Sotrovimab; or their nearest SARS-CoV-2 positive test result to the treatment date was performed in a hospital setting.
Replication	The findings/analyses in this study were not replicated as this was an observational study.
Randomization	No randomization was used as this was an observational study.
Blinding	blinding was not performed in this study as routinely collected healthcare data was used and this was an observational study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging